ALD Nanosolutions (merged with Forge Nano)

Founded by Steven George and Al Weimer

ALD Nanosolutions merged with Forge Nano in January 2021. The company’s innovative Particle ALD Technology, invented at CU Boulder, provides for well-controlled functionalization of particle surfaces at the atomic scale. This platform technology has numerous cutting edge applications in the areas of batteries, catalysis and additive manufacturing, among others. It is currently supported by more than five global companies.

Artimus Robotics jellyfish logo
Artimus Robotics

Founded by Nicholas Kellaris and Christoph Keplinger

Artimus Robotics engineers, designs and manufactures connected hardware that offers intelligent lifelike motion for the next generation of automation, robotics and consumer devices. We make a meaningful and positive impact on the way the world moves for the benefit of both individuals and society.


Arkema logo with blue to green color gradient overlay
Colorado Photopolymer Solutions (merged with Arkema)

Founded by Chris Bowman

Colorado Photopolymer Solutions provides high quality materials and technology development in all areas of photopolymerization. The company develops and manufactures custom photocurable formulations and monomers tailored to meet the needs of individual companies and applications. They also provide consulting services in all areas of photopolymerizations for development of monomers, formulations, specialty polymers and materials, and analytical characterization.

Tree growing up through spiral staircase
Minus Materials

Founded by Shane Frazier and Wil Srubar

Supporting the cement and concrete industries’ sustainability goals. Cement producers have a strong culture of innovation that has led to gains in energy efficiency and new sustainable manufacturing practices that continually reduce environmental impacts. Minus Materials is developing new science and technology to further facilitate sustainable development of the cement and concrete sectors and their value chains through advanced biotechnology.

mosiac logo with cube image on grey background


Founded by Kristi Anseth and Chris Bowman

Mosaic is advancing a fundamentally new class of synthetic materials to support native tissue regeneration. Mosaic expects to significantly impact the field of tissue regeneration, including applications in wound healing, bone regeneration, cartilage repair, stem cell therapy and dermal fillers.


Prometheus Materials

Founded by Mija Hubler and Wil Srubar

Zero Carbon Concrete — We use algae, sunlight, water and sand to produce a bio-cement alternative to traditional cement and concrete that eliminates CO2 emissions.


Respirogen logo with the "o" made out of dissipating molecules

Founded by Mark Borden

Respirogen specializes in novel therapeutic oxygen delivery; stabilizing and delivering ozygen for targeted clinical indications.


Solid Power cube logo with black background

Solid Power, Inc.

Founded by Sehee Lee and Conrad Stoldt

Solid Power is an industry-leading developer of next-generation all-solid-state battery technology. With considerably higher energy and greatly improved safety, all-solid-state batteries have the potential to revolutionize future mobile power markets.


Swift Solar

Swift Solar logo

Founded by Michael McGehee

SwiftSolar builds solar for the next generation. Their mission is to create a world where all energy is clean energy, offering high-performance perovskite tandem technology in any shape and size.


TYNT logo against blue sky background
TYNT Technologies

Founded by  Michael McGehee

TYNT Technologies produces affordable dynamic window technology with neutral color, energy savings and privacy features.



Vitro Logo

Founded by Johnny Hergert, Camila Uzcategui and Bob McLeod

Vitro3D is a company hoping to revolutionize the cancer drug discovery process. Cancer drug development is a long, risky and expensive process because pharmaceutical companies waste billions of dollars in research and development. They test drugs that are doomed to fail while also dismissing viable drugs. A key pain point is that the current gold standard for preclinical drug screening doesn’t accurately represent breast tumor tissue, leading to conflicting results, preclinical delays and late-stage clinical failures.